Best Medical Stocks To Watch Now - August 7th

Key Points

• Eli Lilly and UnitedHealth Group are key medical stocks to watch, with significant market capitalizations of $606.20 billion and $219.79 billion, respectively.
• Novo Nordisk A/S recently traded at $48.68, showing a high trading volume of 33,926,946 shares, indicating strong investor interest.
• Hims & Hers Health operates a telehealth platform and has seen its stock price fluctuate significantly over the past year, with a 52-week low of $13.47 and a high of $72.98.

Eli Lilly and Company, UnitedHealth Group, Novo Nordisk A/S, Hims & Hers Health, and Vertex Pharmaceuticals are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of companies operating in the healthcare sector—this includes pharmaceutical and biotechnology firms, medical device manufacturers, and healthcare service providers. Investors buy and sell these stocks to gain exposure to developments like new drug approvals, cutting-edge treatments, and demographic trends such as an aging population. Their performance is often driven by clinical trial results, regulatory decisions, patent lifecycles, and broader economic conditions. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of LLY traded down $106.74 on Thursday, reaching $639.63. The stock had a trading volume of 21,010,647 shares, compared to its average volume of 3,922,252. The firm has a market capitalization of $606.20 billion, a price-to-earnings ratio of 52.15, a price-to-earnings-growth ratio of 1.09 and a beta of 0.44. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company has a 50-day simple moving average of $777.97 and a 200-day simple moving average of $800.20. Eli Lilly and Company has a 12-month low of $633.20 and a 12-month high of $972.53.

Read Our Latest Research Report on LLY

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

UNH stock traded down $3.49 on Thursday, reaching $242.29. 8,631,189 shares of the company traded hands, compared to its average volume of 12,097,067. UnitedHealth Group has a one year low of $234.60 and a one year high of $630.73. The company has a debt-to-equity ratio of 0.73, a current ratio of 0.85 and a quick ratio of 0.85. The company has a market cap of $219.79 billion, a P/E ratio of 10.50, a price-to-earnings-growth ratio of 1.62 and a beta of 0.43. The firm has a fifty day simple moving average of $293.86 and a 200-day simple moving average of $410.54.

Read Our Latest Research Report on UNH

Novo Nordisk A/S (NVO)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Shares of NVO stock traded up $3.30 on Thursday, reaching $48.68. The stock had a trading volume of 33,926,946 shares, compared to its average volume of 11,205,813. The stock has a market cap of $217.36 billion, a P/E ratio of 14.40, a price-to-earnings-growth ratio of 1.43 and a beta of 0.63. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $139.74. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.56 and a current ratio of 0.74. The company has a 50 day simple moving average of $67.96 and a 200 day simple moving average of $72.01.

Read Our Latest Research Report on NVO

Hims & Hers Health (HIMS)

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

NYSE HIMS traded down $0.54 on Thursday, hitting $50.59. 23,734,022 shares of the company traded hands, compared to its average volume of 34,365,758. The company has a market capitalization of $11.32 billion, a price-to-earnings ratio of 63.07, a P/E/G ratio of 2.06 and a beta of 2.08. The company has a current ratio of 4.98, a quick ratio of 1.32 and a debt-to-equity ratio of 1.72. The business's 50 day moving average price is $53.79 and its 200-day moving average price is $44.63. Hims & Hers Health has a 52-week low of $13.47 and a 52-week high of $72.98.

Read Our Latest Research Report on HIMS

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Shares of Vertex Pharmaceuticals stock traded down $9.18 during trading hours on Thursday, hitting $376.47. The company's stock had a trading volume of 2,404,742 shares, compared to its average volume of 1,614,981. The business has a 50 day moving average price of $453.73 and a two-hundred day moving average price of $466.25. Vertex Pharmaceuticals has a 12-month low of $372.35 and a 12-month high of $519.88. The company has a market cap of $96.68 billion, a PE ratio of 26.94 and a beta of 0.44. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.52.

Read Our Latest Research Report on VRTX

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.